| Literature DB >> 35161188 |
Andreia-Cristina Soare1, Viorica Meltzer1, Claudiu Colbea1, Ioana Stanculescu1, Elena Pincu1.
Abstract
Formulations with two or more active pharmaceutical ingredients (APIs) are a researched trend due to their convenient use compared with multiple medications. Moreover, drug-drug combinations may have a synergistic effect. Drotaverine hydrochloride (D-HCl) is commonly used for its antispasmodic action. The combination of a spasmolytic and an analgesic drug such as ibuprofen (Ibu) or ketoprofen (Ket) could become the answer for the treatment of localized pain. D-HCl:Ibu and D-HCl:Ket drug-drug interactions leading to the formation of eutectic compositions with increased bioavailability, obtained by mechanosynthesis, a green, solvent-free method was explored for the first time. The compatibility of Ibuprofen, Ketoprofen, and Drotaverine Hydrochloride was investigated using differential scanning calorimetry (DSC), X-ray diffraction (XRD), and Fourier-Transform Infrared spectroscopy (FTIR). Solid-liquid equilibrium (SLE) phase diagrams for the binary systems of active pharmaceutical ingredients were developed and the Tammann diagrams were designed to determine the eutectic compositions. The excess thermodynamic functions GE for the pre-, post-, and eutectic compositions were obtained using the computed activity coefficients data. Results show that drotaverine-based pharmaceutical forms for pain treatment may be obtained at 0.9 respectively 0.8 molar fractions of ibuprofen and ketoprofen which is advantageous because the maximum allowed daily dose of Ibu is about 6 times higher than those of D-HCl and Ket. The obtained eutectics may be a viable option for the treatment of pain associated with cancer therapy.Entities:
Keywords: DSC; Drotaverine Hydrochloride; NSAIDs; eutectic; excess functions
Year: 2022 PMID: 35161188 PMCID: PMC8838396 DOI: 10.3390/ma15031244
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1Structural formula for: (a) Ibuprofen (Ibu), (b) Ketoprofen (Ket) and (c) Drotaverine Hydrochloride (D-HCl).
Figure 2DSC curves for Ibuprofen (Ibu), Ketoprofen (Ket) and Drotaverine Hydrochloride (D-HCl).
Melting temperatures and enthalpy of fusion of APIs *.
| Pure Compound | ∆ | ||
|---|---|---|---|
| Lit. | This Study | This Study | |
| Ibuprofen | 349 [ | 348.4 ± 0.2 | 24.91 ± 0.43 |
| Ketoprofen | 366.15 [ | 367.5 ± 0.2 | 27.42 ± 0.32 |
| Drotaverine Hydrochloride | 489.35 [ | 488.4 ± 0.4 | 50.52 ± 0.52 |
*—Results were statistically significant with p-values smaller than 0.05.
Figure 3DSC curves for Ibu and D-HCl and their binary mixtures.
Thermodynamic parameters for Drotaverine Hydrochloride and Ibuprofen system *.
| xIbu | 1st DSC Peak | 2nd DSC Peak | ||
|---|---|---|---|---|
| Δ | ||||
| 0 | - | - | 488.4 | - |
| 0.2 | 343.3 | 14.77 | 474.2 | 2900.5 |
| 0.4 | 343.8 | 31.54 | 457.6 | 4065.4 |
| 0.5 | 343.5 | 51.68 | 443.3 | 3987.2 |
| 0.7 | 343.5 | 75.48 | 412.8 | 3175.2 |
| 0.9 | 343.8 | 111.9 | 343.8 | −615.4 |
| 1 | - | - | 348.4 | - |
*—Results were statistically significant with p-values smaller than 0.05.
Figure 4(A). Phase diagram of binary mixture Ibu—D-HCl: a. ideal behavior; b. real behavior; c. eutectic temperature. (B). Tammann’s plot.
Figure 5DSC curves for Ket and D-HCl and their binary mixtures.
Thermodynamic parameters for Drotaverine Hydrochloride and Ketoprofen system *.
| xKet | 1st DSC Peak | 2nd DSC Peak | ||
|---|---|---|---|---|
| ∆ | ||||
| 0 | - | - | 488.4 | - |
| 0.2 | 343.6 | 8.86 | 474.4 | 2582.4 |
| 0.3 | 347.8 | 14.56 | 460.5 | 2553.5 |
| 0.4 | 347.4 | 18.09 | 447.2 | 2450.0 |
| 0.5 | 342.0 | 26.03 | 432.2 | 2102.5 |
| 0.7 | 349.3 | 62.82 | 374.8 | −1217.7 |
| 0.8 | 344.1 | 94.02 | 344.1 | −1828.0 |
| 0.9 | 353.2 | 57.44 | 365.2 | −470.1 |
| 1 | - | - | 367.4 | - |
*—Results were statistically significant with p-values smaller than 0.05.
Figure 6(A). Phase diagram of binary mixture Ket—D-HCl: a. ideal behavior; b. real behavior; c. eutectic temperature. (B) Tammann’s plot.
Main XRD relative intensities for nanoparticles single components and mixtures *.
| Ket | Ibu | D-HCl | |||
|---|---|---|---|---|---|
|
|
|
|
|
|
|
| 23 | 100 | 6 | 100 | 14.5 | 100 |
| 18.5 | 79.3 | 22.3 | 81.4 | 22 | 60 |
| 22 | 69.4 | 16 | 65.4 | 44 | 28.57 |
| 6.5 | 46.2 | 20.4 | 52.7 | 65 | 25.42 |
| 19.5 | 51.3 | 12.3 | 30.7 | 77 | 27.71 |
*—Results were statistically significant with p-values smaller than 0.05.
Figure 7FTIR spectra of (a) Ketoprofen, (b) Ibuprofen, (c) Drotaverine hydrochloride, (d) Ketoprofen- Drotaverine hydrochloride (e) Ibuprofen-Drotaverine hydrochloride.
FTIR absorption peaks for Ibu, D-HCl, and Ket and band assignments (v-stretching, δ-deformation).
| Ibu | D-HCl | Ket | |||
|---|---|---|---|---|---|
|
|
|
| |||
| 2955 | νCH3 antisymmetric | 3500–3300 | νN-H secondary amine | 3054 | νC-H |
| 1708 | νC=O | 3000–2840 | νC-H | ||
| 1507 | νC=C aromatic | 1650–1580 | δ N-H | 1694 | νC=O |
| 1418 | δCH-CO | 1600–1475 | νC=C aromatic | 1654 | νC=O (ketone) |
| 1329 | δOH in plane | 1260–1000 | νC-O | 15,898 | νC=C aromatic |
| 1230 | νC-C | 1442 | νC=C aromatic | ||
| 934 | δCH3 rocking | ||||
| 866 | δC-H out of plane | ||||
| 779 | δCH2 rocking | ||||
| 668 | δC-H out of plane | ||||